Simplivia Healthcare News
4 articles
growth-positive
פימי תנפיק את סימפליויה בשווי של פי 7 לעומת הרכישה מטבע כלכליסט
Simplivia, a medical equipment manufacturer, is planning to raise 300 million NIS in an IPO on the Tel Aviv Stock Exchange, valuing the company at 1.2 billion NIS. The company was acquired by FIMI, Phoenix Insurance Company, and Bank Leumi in 2019 for 170 million NIS. Simplivias products, which protect medical staff from exposure to dangerous substances, are sold in over 30 countries. The companys annual sales volume is 250 million NIS, and together with Novamed, which it acquired a controlling stake in 2021, sales reach 400 million NIS.
InvestmentPublic Trading
growth-positive
Simplivia Healthcare buys diagnostics co Novamed
Simplivia Healthcare Ltd., a drug delivery company, has acquired 70% of diagnostics company Novamed at a valuation of NIS 24 million. The acquisition was facilitated by Value Base M&A Israel. Simplivia develops and manufactures closed system transfer devices to protect medical professionals from exposure to hazardous drugs. Novamed is an Israeli developer and manufacturer of diagnostic platforms. The acquisition will allow Novamed to expand its global reach through Simplivias marketing channels and expertise in the medical device field.
Acquisition
growth-positive
FIMI sells 33% of medical equipment co Simplivia
Private equity firm FIMI Opportunity Funds has sold 33% of the shares in healthcare company Simplivia to The Phoenix Holdings Ltd. and Leumi Partners for $47 million, at a company valuation of $140 million. FIMI bought the business from Teva Pharmaceutical Industries and set up Simplivia in 2019 at an investment of $47.5 million. FIMI has made a return of $67 million on its investment and will continue to hold 65% of the company.
Acquisition
growth-positive
FIMI completes acquisition of Teva's Kiryat Shmona plant
FIMI Opportunity Funds has completed the acquisition of the Migada plant in Kiryat Shmona from Teva Pharmaceutical Industries for $47.5 million. The acquired plant, Tevadaptor, produces a closed system for protecting medical teams against exposure to hazardous materials. Ori Yehudai, former CEO of Frutarom, will join Tevadaptor as chairman. Tevadaptor currently has 200 employees and is profitable. Tevas streamlining plan aims to save $3 billion in costs and reduce debt. Tevas market cap is $16.6 billion.
Acquisition
